These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 16675478)

  • 1. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
    Akasu T; Moriya Y; Ohashi Y; Yoshida S; Shirao K; Kodaira S;
    Jpn J Clin Oncol; 2006 Apr; 36(4):237-44. PubMed ID: 16675478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
    Oki E; Kakeji Y; Yoshida R; Ikeda K; Nishida K; Koga T; Egashira A; Tokunaga E; Morita M; Baba H; Maehara Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():138-43. PubMed ID: 16897990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.
    Kim YS; Kim JH; Yoon SM; Choi EK; Ahn SD; Lee SW; Kim JC; Yu CS; Kim HC; Kim TW; Chang HM
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):796-802. PubMed ID: 19289261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin.
    de la Torre A; García-Berrocal MI; Arias F; Mariño A; Valcárcel F; Magallón R; Regueiro CA; Romero J; Zapata I; de la Fuente C; Fernández-Lizarbe E; Vergara G; Belinchón B; Veiras M; Molerón R; Millán I
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):102-10. PubMed ID: 17869446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
    Thomschke D; Kyau-Ummen B; Halbfass HJ
    Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
    Hasegawa K; Takayama T; Ijichi M; Matsuyama Y; Imamura H; Sano K; Sugawara Y; Kokudo N; Makuuchi M
    Hepatology; 2006 Oct; 44(4):891-5. PubMed ID: 17006925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.
    Atasoy BM; Abacioglu U; Dane F; Ozgen Z; Yumuk PF; Ozden S; Akgun Z; Mayadagli A; Basaran G; Turhal S; Sengoz M
    J BUON; 2007; 12(2):203-8. PubMed ID: 17600873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
    Cafiero F; Gipponi M; Lionetto R;
    J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
    Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
    Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up.
    Fernández-Martos C; Aparicio J; Bosch C; Torregrosa M; Campos JM; Garcera S; Vicent JM; Maestu I; Climent MA; Mengual JL; Tormo A; Hernandez A; Estevan R; Richart JM; Viciano V; Uribe N; Campos J; Puchades R; Arlandis F; Almenar D
    J Clin Oncol; 2004 Aug; 22(15):3016-22. PubMed ID: 15210740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
    Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
    Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of long-term survival after resection of advanced undifferentiated rectal cancer treated by short-term preoperative chemoradiotherapy and postoperative adjuvant chemotherapy].
    Naito Y; Hashiguchi Y; Ueno H; Kajiwara Y; Shimazaki H; Mochizuki H; Hase K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):117-20. PubMed ID: 21368471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Compatibility, indications, and limits of nerve sparing technique in lateral pelvic lymphadenectomy for advanced rectal carcinoma].
    Di Matteo FM; Peparini N; Maturo A; Zeri KP; Torretta A; Mascagni D; Redler A; Di Matteo G
    Chir Ital; 2000; 52(3):203-13. PubMed ID: 10932364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre randomised study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer.
    Arima S; Ohsato K; Hisatsugu T; Shimura H
    Eur J Surg; 1994 Apr; 160(4):227-32. PubMed ID: 8049313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
    Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
    Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
    Smalley SR; Benedetti JK; Williamson SK; Robertson JM; Estes NC; Maher T; Fisher B; Rich TA; Martenson JA; Kugler JW; Benson AB; Haller DG; Mayer RJ; Atkins JN; Cripps C; Pedersen J; Periman PO; Tanaka MS; Leichman CG; Macdonald JS
    J Clin Oncol; 2006 Aug; 24(22):3542-7. PubMed ID: 16877719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.